Shares of Homology Medicines, Inc. (NASDAQ:FIXX – Get Rating) have earned a consensus recommendation of “Hold” from the ten research firms that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target […]
Homology Medicines (NASDAQ:FIXX – Get Rating) had its price objective reduced by analysts at Credit Suisse Group to $2.10 in a research report issued to clients and investors on Tuesday, Stock Target Advisor reports. The firm presently has a “neutral” rating on the stock. Credit Suisse Group’s target price suggests a potential upside of 45.83% […]
- $130 Million in Non-Dilutive Capital Strengthened Financial Position - - Presentations at Upcoming ASGCT Annual Meeting Include First-Time Details of.
Homology Medicines, Inc. (NASDAQ:FIXX – Get Rating) has been given a consensus rating of “Buy” by the eleven analysts that are covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have […]
- Multiple Presentations Feature HMI-103 Phase 1 Investigational Therapy for PKU, Including Genome-Wide Integration Assays to Confirm No Off-Target Editing.